Green Tea Extract Restrains Cancer in Most CLL cases

This is the recent in a succession of Mayo researches to exhibit potential of using EGCG or epigallocatechin gallate – the key constituent in green tea in lowering numbers of leukemia cells in CLL (chronic lymphocytic leukemia) patients. Mayo Clinic study firstly evaluated the green tea extract, EGCG in an array of lab assays around 8 years back and was noted to lower the survival rate in CLL cells. The lab discovery was then ensued by a triumphant first phase scientific study – the foremost instant when a green tea extract have been employed in CLL-afflicted patients.

Doctor Tait Shanafelt, specialist in the field of hematology and helming the trial stated that solely a relative phase three study could ascertain if EGCG could postpone advancement of CLL though the gains which have been noted in majority of the CLL cases who employed the green tea extract indicate that it has favourable clinical activity and might be beneficial to stabilize a leukemia type and thus potentially slacken it.

Doctor Neil Kay, a haematologist and study investigator whose lab firstly conducted tests of EGCG in leukemia blood cells from CLL cases stated that the use of toxin-free chemical substances for reverting cancerous development for postponing the requirement of toxic treatment is a worthwhile objective in oncology study – especially for cancer types whose earlier management were observation-based like CLL.

The duo doctors have cautioned that the green tea extract is not an alternative to chemotherapy. The Mayo study entrants who underwent treatment with EGCG were in the initial staging, non-symptomatic CLL patients that had would not have undergone treatment till their condition advanced.

Chronic lymphocytic leukemia is a blood cancer type which is a cross in-between lymphoma and leukemia. Advancement of the condition is evaluated by the amounts of leukemic cells in the bloodstream and bone marrow alongside enlarged lymph nodes because of the leukemic cells penetrating.

During the first phase of the trial that appeared in the ‘Journal of Clinical Oncology’, investigators noted that the leukemic cell count lessened in 1/3rd of the candidates and that most of the entrants with lymph node enlargement because of connection with CLL noted a fifty percent or more lessening in the size of lymph nodes.

Employing the max dosage evaluated in the first phase of the clinical trial, the investigators unveiled their second phase of scientific study in extra thirty-six patients. The study evaluated the outcomes of such thirty-six entrants along with 6 patients from the initial phase of the study treated at the analogous dosage. Outcomes from forty-one patients who concluded the trial revealed that thirty-one percent of patients had a twenty percent or more continual lowering in blood lymphocyte count and sixty-nine percent of patients having lymph node enlargement noticed a lowering in node size of fifty percent or more.

The doctors pointed out that overall the therapy was ably tolerated and carried mild-ranging side-effects in majority of the patients.

Researchers point out that a third phase of scientific study is necessary prior to EGCG being recommended to CLL patients. However those keen on taking supplements must seek oncologist consultation and require apt supervision employing lab tests.

Popularity: 4% [?]